Niven Ralph's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Nov 9, 2022
- Accession no.
- 0001415889-22-011246
- Filed
- Nov 9, 2022
- Trade date
- Nov 7, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 5 derivative transactions. Open-market sales total $43.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niven RalphCIK 0001168060 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2022 | Common Stock | MOption exerciseAcquired | +650 | $1.74 | +$1,131 | 2,259 | Direct | |
| Nov 7, 2022 | Common Stock | MOption exerciseAcquired | +1,600 | $2.14 | +$3,424 | 3,859 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −450 | $17.09F2 | −$7,690.5 | 3,409 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −155 | $18.02F3 | −$2,793.1 | 3,254 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −1,430 | $19.82F4 | −$28,342.6 | 1,824 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −215 | $20.29F5 | −$4,362.35 | 1,609 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2022 | Common Stock | MOption exerciseDisposed | −450 | $0.00 | $0 | 22,308 | Direct | |
| Nov 7, 2022 | Common Stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 13,688 | Direct | |
| Nov 7, 2022 | Common Stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 15,494 | Direct | |
| Nov 7, 2022 | Common Stock | MOption exerciseDisposed | −650 | $0.00 | $0 | 47,308 | Direct | |
| Nov 7, 2022 | Common Stock | MOption exerciseDisposed | −750 | $0.00 | $0 | 56,732 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.67 to $17.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.70 to $18.62, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.15 to $20.14, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.21 to $20.51, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.